SuperworthRapport Therapeutics EPS RAPP
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$3.04
- Latest quarter, Q2 FY26
- −$1.19
- Fiscal year 2025
- −$2.86
Rapport Therapeutics' earnings per share was −$3.04 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.19.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.86 | n/a |
| FY2024 | −$13.84 | n/a |
| FY2023 | −$22.67 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.19 | n/a | −$3.04 | |
| Q1 FY26 | −$0.42 | n/a | −$2.60 | |
| Q4 FY25 | −$0.72 | n/a | −$2.86 | |
| Q3 FY25 | −$0.71 | n/a | −$2.71 | |
| Q2 FY25 | −$0.75 | n/a | −$2.50 | |
| Q1 FY25 | −$0.68 | n/a | −$3.45 | |
| Q4 FY24 | −$0.57 | n/a | −$13.84 | |
| Q3 FY24 | −$0.50 | n/a | −$21.28 | |
| Q2 FY24 | −$1.70 | n/a | −$26.48 | |
| Q1 FY24 | −$11.07 | n/a | −$29.23 | |
| Q4 FY23 | −$8.01 | n/a | −$22.67 | |
| Q3 FY23 | −$5.70 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Rapport Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RAPPRapport Therapeutics | −$3.04 | |
| OMEROmeros | $1.52 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| ABUSArbutus Biopharma | $0.78 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| Peer median | $2.07 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Rapport Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.